DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

B. Riley FBR Maintains Neutral on CymaBay Therapeutics, Lowers Price Target to $1.5

B. Riley FBR analyst Mayank Mamtani maintains CymaBay Therapeutics (NASDAQ:CBAY) with a Neutral and lowers the price target from $2 to $1.5.

Benzinga · 03/18/2020 11:00

B. Riley FBR analyst Mayank Mamtani maintains CymaBay Therapeutics (NASDAQ:CBAY) with a Neutral and lowers the price target from $2 to $1.5.